MeduGate LMS;

5th Oct, 2026 12:00 AM

Test

Pirtobrutinib Gains First-Line Nod for CLL/SLL

The FDA has approved pirtobrutinib (Jaypirca, Eli Lilly) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.

Pirtobrutinib was previously approved for CLL/SLL after at least two prior lines of therapy including a Bruton tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor.

With the new indication, pirtobrutinib joins the covalent BTK inhibitors acalabrutinib, zanubrutinib, and ibrutinib, as first-line CLL/SLL options. Unlike pirtobrutinib, their indications do not exclude patients with chromosome 17p deletions.

Still, Lilly says pirtobrutinib has an advantage over its covalent BTK rivals: As a noncovalent inhibitor, its reversible binding allows it to retain activity against BTK mutations that can drive resistance to acalabrutinib, zanubrutinib, and ibrutinib.

Article Key Points

FDA approves pirtobrutinib for untreated CLL/SLL with no known 17p deletion.
First-line option joins acalabrutinib, zanubrutinib, ibrutinib; pirtobrutinib is noncovalent BTK inhibitor.
BRUIN CLL-313: 282 pts; PFS not reached vs 33.5 mo with bendamustine-rituximab.
OS not reached in either arm; deaths 3 with pirtobrutinib vs 10 with BR.
Common AEs: URTI 27%, rash 22%, COVID 21%; neutropenia most common grade 3/4 lab abnormality.

Dive Deeper

How does pirtobrutinib compare with venetoclax-based frontline CLL therapy?

Which BTK mutations predict resistance to covalent inhibitors?

What are long-term cardiovascular risks with noncovalent BTK inhibition?

Approval was based on the BRUIN CLL-313 trial in 282 previously untreated patients randomized evenly to pirtobrutinib until disease progression or to bendamustine plus a rituximab product (BR) for six cycles. BR was a common first-line option when the trial was launched but has since been largely replaced by targeted approaches, including BTK inhibitors and venetoclax-based regimens. Patients with 17p deletions were excluded because BR wasn't considered appropriate treatment for them.

SUGGESTED FOR YOU

After a median follow-up of 28 months, median progression-free survival was not reached in the pirtobrutinib arm vs 33.5 months with BR. Median overall survival was not reached in either group, with three deaths in the pirtobrutinib arm and 10 with BR.

The most common adverse events in the pirtobrutinib arm were upper respiratory tract infections (27%), rash (22%), and COVID (21%); 28% of patients had serious adverse events, including pneumonia (5%). Neutropenia was the most common grade 3 or 4 lab abnormality.

Labeling includes warnings and precautions for infections, hemorrhage, cytopenias, cardiac arrhythmias, secondary primary malignancies, hepatotoxicity, and embryo-fetal toxicity.

Pirtobrutinib is dosed at 200 mg orally once daily until disease progression or unacceptable toxicity.

M. Alexander Otto is a physician assistant and award-winning journalist. He is also an MIT science journalism fellow. Email: aotto@medscape.net

Dive Deeper

Commonly Asked by HCPs

Q: How do covalent and noncovalent BTK inhibitors differ in CLL management?

A: Covalent BTK inhibitors bind irreversibly to BTK, while noncovalent agents bind reversibly and may retain activity against some resistance mutations. This distinction is clinically relevant when considering prior BTK exposure, resistance mechanisms, and sequencing of therapy in relapsed or refractory disease.

Read full answer

Q: Which patients with CLL/SLL should avoid chemoimmunotherapy-based first-line regimens?

A: Chemoimmunotherapy is generally less favored in patients with high-risk biology, older age, frailty, or significant comorbidity because targeted regimens usually offer better disease control and tolerability. Patient selection also depends on marrow reserve, infection risk, renal function, and the likelihood of durable benefit from a time-limited approach.

Read full answer

Q: What are current first-line treatment options for untreated CLL/SLL?

A: First-line CLL/SLL treatment is now typically centered on targeted therapy rather than chemoimmunotherapy. Common options include BTK inhibitors and venetoclax-based regimens, with selection driven by comorbidities, cardiac risk, bleeding risk, renal function, and treatment goals such as continuous versus time-limited therapy.

Read full answer

Q: How should clinicians choose therapy for CLL/SLL with TP53 or 17p abnormalities?

A: TP53 disruption or 17p deletion generally identifies higher-risk CLL/SLL and often shifts treatment away from chemoimmunotherapy toward targeted agents. Clinical decision-making usually emphasizes biologic risk, expected depth and durability of response, prior therapy exposure, and the safety profile of available targeted options.

Read full answer

Q: What adverse effects and monitoring are important with BTK inhibitor therapy?

A: BTK inhibitor therapy requires monitoring for infections, cytopenias, bleeding, atrial arrhythmias, hypertension, and liver toxicity. Ongoing assessment usually includes blood counts, clinical infection surveillance, medication review for anticoagulants or antiplatelets, and attention to secondary malignancy risk and reproductive safety.

Read full answer